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Aims: To investigate whether treatment of coexisting
asthma has any effect on the incidence of hypoglycaemia
and on glycaemic control in children with type 1 diabetes.
Methods: An observational study of children attending the
paediatric diabetes clinics of five hospitals in the North
Trent Region. Information on the frequency of hypoglycae-
mia in the preceding three months, treatment for asthma,
and the individual’s latest HbA1c, was recorded when
they attended for review.
Results: Data were collected on 226 children, of whom
27 (12%) had treated asthma. Only 11/27 children with
asthma were taking their prescribed inhaled steroids. All
used β agonists at least once a week. There was a reduc-
tion of 20% in the incidence of hypoglycaemia in the dia-
betic children with treated asthma. Of the children with
diabetes and treated asthma, 52% reported an episode of
hypoglycaemia in the previous three months compared to
72% of those with only diabetes. There was no difference
in the proportion of children experiencing nocturnal or
severe hypoglycaemia. Although not significant, those with
asthma and diabetes also had better overall control
(HbA1c 8.8%) compared to those with diabetes alone
(HbA1c 9.3%).
Conclusions: Diabetic children with treated asthma have
significantly fewer episodes of hypoglycaemia and better
glycaemic control compared to children with diabetes
alone. This observation needs further investigation but
raises an interesting question. Do the drugs used to treat
asthma, in particular β agonists, have the therapeutic
potential to reduce hypoglycaemia and facilitate an
improvement in glycaemic control?
Beta agonists, together with inhaled steroids, are widelyused in the treatment of asthma in children. The effect ofsteroids on blood sugar is well documented. Beta agonists
can also have a significant effect on blood sugar.1 They have a
direct glycaemic effect and an indirect effect on blood glucose
by enhancing sympathetically mediated counter regulatory
responses to hypoglycaemia.2 Nebulised salbutamol can
significantly increase blood glucose, and cases of ketoacidosis
have been reported in diabetics.3 Terbutaline has been shown
to be as effective as glucagon in reversing hypoglycaemia; in
adults, under experimental conditions, it has proved effective
in preventing nocturnal hypoglycaemia.4 5 The potential for
asthma treatment to influence hypoglycaemia and diabetic
control prompted us to study our paediatric diabetic popula-
tion, to examine whether treatment of coexisting asthma had
any effect on the incidence of hypoglycaemia and on
glycaemic control.
PATIENTS AND METHODS
All children had type 1 diabetes and were attending the pae-
diatric diabetes clinics of five hospitals in the North Trent
Health Region of the UK. Information on the incidence of
hypoglycaemia within the past three months, asthma
treatment if any, and the individual’s latest HbA1c, were
recorded for all children with diabetes when they attended for
review. The results for those children on treatment for asthma
were compared to those of the clinic population as a whole
using χ2 tests and unpaired t tests. Treated asthma was defined
as being prescribed inhaled steroids or using β agonists at least
once a week. Individuals who used treatment only during viral
exacerbations or who had been treated for asthma in the past
were not considered to be currently on treatment. Few
children check their blood glucose during episodes of
hypoglycaemia, so a pragmatic approach to the definition of
hypoglycaemia was adopted. Episodes reported by the child
and their family as “hypos” were accepted as such. Only for
severe hypoglycaemia was a definition stipulated, which was
an episode requiring glucagon or dextrose gel.
RESULTS
Data were collected on 226 children with diabetes. Twenty
seven children were on treatment for asthma and the
prevalence of asthma reflects that of the general population at
12%.6 Interestingly only 11/27 children prescribed inhaled
steroids were using them regularly, although they used β ago-
nists at least once a week. The mean age for those with both
asthma and diabetes was 11.3 years (SD 3.3) compared to 11.5
years (SD 3.6) for those with diabetes alone. Table 1 presents
details of the impact of treated asthma on hypoglycaemia and
glycaemic control. There was a statistically significant
reduction of 20% in the incidence of hypoglycaemia in those
diabetic children with treated asthma. Of those children with
both diabetes and treated asthma, 52% reported an episode of
hypoglycaemia in the previous three months compared to 72%
of those with diabetes alone (p < 0.05). There was no
difference between the groups in the proportion of children
experiencing nocturnal hypoglycaemia or severe hypoglycae-
mia. Although not statistically significant, those with asthma
and diabetes also tended to have better overall control (HbA1c
8.8%, 95% CI 8.4 to 9.3) compared to those with diabetes alone
(HbA1c 9.3%, 95% CI 9.0 to 9.5).
Analysis of the influence of age, frequency of β agonist use,
and of inhaled steroids on hypoglycaemia in asthmatics was
limited by the small sample size. There were no statistically
significant differences, but this may be a consequence of the
small numbers. Hypoglycaemia was reported by only 30%
(3/10) of frequent users of β agonists compared to 58% (7/12)
of less frequent users (p = 0.18). Of those using inhaled ster-
oids, 63% (7/11) reported hypoglycaemia compared to 38%
(5/13) of those not taking inhaled steroids (p = 0.29). Mean
HbA1c was 9.0% (0.6%) and 8.6% (0.7%) respectively.
DISCUSSION
Given the tendency of both steroids and β agonists to elevate
blood glucose, we had anticipated that if coexistent treatment
for asthma were to influence diabetic control, we would
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perhaps see a reduction in the incidence of hypoglycaemia but
at the expense of an elevation in HbA1c. We observed a
significant reduction in hypoglycaemic episodes associated
with a tendency to improvement in HbA1c. It may be that it is
the pathological process associated with asthma that facili-
tates a reduction in hypoglycaemia, but we are not aware of a
mechanism to explain this phenomenon. It is more likely that
there is a beneficial effect of the treatment associated with
asthma. This finding, if confirmed, has potential for the man-
agement of type 1 diabetes.
The study does have methodological weaknesses, which
need to be acknowledged, but which should not adversely
affect the results. This was an observational study of our local
paediatric population and different laboratories were used for
HbA1c measurements. As the proportion of children with
treated asthma was similar between the centres, any discrep-
ancy in HbA1c assays should be equally represented in both
groups and should not influence the study’s findings.
Similarly we adopted a pragmatic definition of hypoglycae-
mia, relying on children and their families to define an
episode. Any variation in definition of hypoglycaemia should
again be consistent across the patient population and should
not bias the results.
An alternative explanation is that the relation between
asthma and diabetes may in some way modify compliance
with insulin therapy, alter patterns of exercise, and influence
parental involvement. Children with symptomatic asthma
may exercise less and as a consequence experience less
exercise related hypoglycaemia. Having two chronic condi-
tions may increase parental imput and hence improve diabetic
control. It is possible that these factors rather than treatment
for asthma may be influencing hypoglycaemia, but we did not
attempt to address them in this study.
Considering the potent direct and indirect glycaemic effects
of β agonists, we would suggest that they are the most prob-
able candidate as mediator of the reduction in hypoglycaemia
we observed. Fewer than half the children in the study with
asthma were using inhaled steroids, and although not statisti-
cally significant, there was an increased incidence of hypogly-
caemia in those asthmatics using inhaled steroids compared
to those who did not. Frequent users of β agonists had fewer
episodes of hypoglycaemia than less frequent users. Reducing
hypoglycaemia may facilitate an improvement in overall
glycaemic control, perhaps by reducing hypoglycaemia
unawareness.7 Such a mechanism would explain the small
improvement in HbA1c we observed.
Hypoglycaemia remains one of the principle obstacles to
tight glycaemic control. The evidence is by no means
conclusive and these observations need further investigation,
but they raise an interesting question. Do the drugs used to
treat asthma, in particular β agonists, have the therapeutic
potential to reduce hypoglycaemia and facilitate an improve-
ment in glycaemic control?
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Table 1 Differences between diabetic children with treated asthma and the rest of
the paediatric diabetic clinic population in the incidence of hypoglycaemia and
HbA1c
Children with asthma
and diabetes (n=27)
Children with diabetes
alone (n=176)
Mean age, y (SD) 11.3 (3.3) 11.5 (3.6)
Percentage of children reporting daytime
hypoglycaemia in the past 3 months
52%* 72%*
Percentage of children reporting nocturnal
hypoglycaemia in the past 3 months
26% 28%
Percentage of children reporting severe hypoglycaemia
in the past 3 months
11% 10%
Mean HbA1c (95% CI) 8.8% (8.4 to 9.3) 9.3% (9.0 to 9.5)
*p<0.05.
156 Wright, Wales
www.archdischild.com
